全球萊姆病診斷市場：COVID-19 的增長、趨勢、影響和預測（2022-2027 年）

全球萊姆病診斷市場預計在預測期內的複合年增長率為 5.5%。

推動市場增長的主要因素是萊姆病患病率的上升、新的萊姆病診斷測試的出現、新的媒介疾病數量的增加以及政府力度的加強。這包括醫療器械的增加花費。

本報告調查了全球萊姆病診斷市場，提供市場概況、市場增長和製約因素分析、診斷技術/最終用戶/地區分析、競爭形勢等。它提供了全面的信息，例如主要公司簡介。

目錄

第一章介紹

第二章調查方法

第 3 章執行摘要

第四章市場動態

• 市場概況
• 市場促進因素
  • 萊姆病患病率增加
  • 有利於醫療機構的政策
  • 一種新的萊姆病診斷測試的出現
• 市場製約因素
  • 對疾病缺乏關注
• 波特五力分析

第 5 章市場細分

• 通過診斷技術
  • 血清檢測
  • 淋巴細胞轉化試驗
  • 尿抗原檢測
  • 免疫螢光染色
  • 核酸檢測
• 最終用戶
  • 醫院
  • 臨床研究所
• 地區
  • 北美
  • 歐洲
  • 亞太地區
  • 中東和非洲
  • 南美洲

第6章競爭態勢

• 公司簡介
  • Abbott
  • Bio-Rad Laboratories, Inc.
  • Covance Inc.
  • F. Hoffmann-La Roche AG
  • T2 Biosystems, Inc
  • Oxford Immunotec USA, Inc.

第7章 市場機會與動向

The Lyme Disease Diagnostic Market is expected to register a CAGR of 5.5% during the forecast period. The Lyme disease diagnostic market is growing at a good rate owing to factors such as rise in prevalence of lyme disease and emergence of new lyme diagnostic tests. A Lyme disease is a caused by the bacterium borrelia burgdorferi and transmitted through a bite of infected blacklegged deer tick in humans. Several test such as ELISA test used to detect antibodies to B. burgdorferi. If the ELISA test is positive, then further Western blot test is carried out to detect proteins of B. burgdorferi. Moreover, increasing number of cases of tick born diseases is also promoting the growth of lyme disease diagnostic market. For instance, in 2018, according to Centers for Disease Control and Prevention number of cases of tick-borne diseases reported was 47,743, leading to adoption of lyme disease diagnostic tests. Furthermore, rising incidences of new vector borne diseases, growing givernment initiatives and rising healthcare expenditure are some more factors which are fueling the market growth.

Key Market Trends

Serological​ test Segment is Expected to be a largest growing segment in the Lyme Disease Diagnostic Market.

Serological test is a diagnostic method that is particularly used for identifying antibodies and antigens in patients sample which can be serum, plasma, semen and saliva.

Serological test is expected to dominant the segment as this test is highly preferable among all the test owing to measures the antibodies in the late phase of the illness when both nucleic acid test and polymerase chain reaction test is negative. These tests are very beneficial in terms of evaluating Lyme disease. Serological tests includes ELISA, agglutination, precipitation and western blot methods used to identify infectious diseases. Moreover, rising prevalence lyme disease and growing demand of diagnostic tests among targeted patient pool opt for this test and promote the lyme disease diagnostic market.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to hold a significant market share in the global lyme disease diagnostic market. This can be attributed to increasing prevalence of tick borne diseases, increasing initiatives by government and private institute for diagnosing the yme disease in this region. For instance, according to Centers for Disease Control and Prevention(CDC), around 300000 people were diagnosed with Lyme disease every year in North America. Furthermore, increasing healthcare expenditure and presence of well-established healthcare infrastructure is also fuelling the growth of the overall regional market to a large extent.

Competitive Landscape

The Lyme Disease Diagnostic Market is moderately competitive and consists of several major players. In terms of market share, few of the major players are currently dominating the market. Some of the companies which are in the market are T2 Biosystems, Inc, Abbott, Bio-Rad Laboratories, Inc., Graphene Frontiers, Oxford Immunotec USA, Inc., Covance Inc. and ROCHE DIAGNOSTICS INTERNATIONAL LTD.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 Study Assumptions
• 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rise in Prevalence of Lyme disease
  • 4.2.2 Favourable government towards healthcare facilities
  • 4.2.3 Emergence of new lyme diagnostic tests
• 4.3 Market Restraints
  • 4.3.1 Lack of Awarness regarding the disease
• 4.4 Porter's Five Force Analysis
  • 4.4.1 Threat of New Entrants
  • 4.4.2 Bargaining Power of Buyers/Consumers
  • 4.4.3 Bargaining Power of Suppliers
  • 4.4.4 Threat of Substitute Products
  • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

• 5.1 By diagnostic technology
  • 5.1.1 Serological test
    • 5.1.1.1 ELISA
    • 5.1.1.2 Western Blot
  • 5.1.2 Lymphocytic transformation test
  • 5.1.3 Urine Antigen Testing
  • 5.1.4 Immunofluorescent staining
  • 5.1.5 Nucleic acid test
• 5.2 By End User
  • 5.2.1 Hospitals
  • 5.2.2 Clinical laboratories
• 5.3 Geography
  • 5.3.1 North America
    • 5.3.1.1 United States
    • 5.3.1.2 Canada
    • 5.3.1.3 Mexico
  • 5.3.2 Europe
    • 5.3.2.1 Germany
    • 5.3.2.2 United Kingdom
    • 5.3.2.3 France
    • 5.3.2.4 Italy
    • 5.3.2.5 Spain
    • 5.3.2.6 Rest of Europe
  • 5.3.3 Asia-Pacific
    • 5.3.3.1 China
    • 5.3.3.2 Japan
    • 5.3.3.3 India
    • 5.3.3.4 Australia
    • 5.3.3.5 South Korea
    • 5.3.3.6 Rest of Asia-Pacific
  • 5.3.4 Middle-East and Africa
    • 5.3.4.1 GCC
    • 5.3.4.2 South Africa
    • 5.3.4.3 Rest of Middle-East and Africa
  • 5.3.5 South America
    • 5.3.5.1 Brazil
    • 5.3.5.2 Argentina
    • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

• 6.1 Company Profiles
  • 6.1.1 Abbott
  • 6.1.2 Bio-Rad Laboratories, Inc.
  • 6.1.3 Covance Inc.
  • 6.1.4 F. Hoffmann-La Roche AG
  • 6.1.5 T2 Biosystems, Inc
  • 6.1.6 Oxford Immunotec USA, Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS